

**LEGISLATIVE FISCAL OFFICE**  
**Fiscal Note**



Fiscal Note On: **SB 224** SLS 24RS 354

Bill Text Version: **ENROLLED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

<b>Date:</b> May 28, 2024	9:18 AM	<b>Author:</b> OWEN, ROBERT
<b>Dept./Agy.:</b> LDH		<b>Analyst:</b> Shawn Hotstream
<b>Subject:</b> Opioid alternatives		

PHARMACEUTICALS

EN NO IMPACT See Note

Page 1 of 1

Provides relative to opioid alternatives. (8/1/24)

Proposed law provides that LDH shall not establish more restrictive or more extensive utilization controls, including but not limited to more restrictive or more extensive prior authorization of step therapy requirements for clinically appropriate non opioid drugs than the least restrictive utilization controls applicable to any clinically appropriate opioid drug.

Proposed law requires LDH to provide education, and technical assistance on the advantages of non opioid alternative drugs, and collaborate with political subdivisions and agencies to seek funding opportunities for educational and health care services related to non opioid alternatives.

EXPENDITURES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

  

REVENUES	2024-25	2025-26	2026-27	2027-28	2028-29	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Local Funds	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
<b>Annual Total</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>	<b>\$0</b>

**EXPENDITURE EXPLANATION**

There is no anticipated direct material effect on Medicaid expenditures as a result of this measure. The department is required to provide education, awareness, or technical assistance to political subdivisions or agencies on the advantages of non opioid alternative drugs. This measure does not remove the prior authorization process for such non opioid alternative agents.

**REVENUE EXPLANATION**

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate

Dual Referral Rules

House

13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}

6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}

13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

**Patrice Thomas**  
**Deputy Fiscal Officer**